Investigation in Progress — No Complaint Filed Yet
BG&G is actively investigating potential securities fraud claims against Iovance Biotherapeutics, Inc.. If a complaint is filed, this page will be updated. Investors are encouraged to contact us now to preserve their rights.
Why Is Iovance Biotherapeutics, Inc. (IOVA) Under Investigation?
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of shareholders of Iovance Biotherapeutics, Inc. (NASDAQ: IOVA).
On October 29, 2026, Iovance reported results from its Phase 2 IOV-LUN-202 clinical trial of lifileucel, an investigational tumor-infiltrating lymphocyte therapy, in patients with previously treated non-squamous non-small cell lung cancer. In contrast with its previous announcement that data was “Positive”, Iovance now claimed that data was “Consistent with Previously Reported Results”. Among other items, Iovance reported that one of the trial’s subgroups responded at 11.4%, while the treatment such patients normally receive produces a response rate of 12.8%. Following this news, Iovance’s stock price fell $5.25 per share, or 35.45%, to close at $9.56 per share on October 29, 2026.
What Potential Securities Violations Is BG&G Investigating?
- Whether Iovance Biotherapeutics, Inc. and certain of its officers made false or misleading statements regarding the Company's financial condition and business prospects.
- Whether Iovance Biotherapeutics, Inc. failed to disclose material adverse information that would have been significant to a reasonable investor.
- Whether the Company's earnings guidance was supported by a reasonable factual basis at the time it was made.
What Should Iovance Biotherapeutics, Inc. (IOVA) Investors Do?
How Is Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) Stock Trading Today?
Interactive chart showing the weekly share price history of NASDAQ:IOVA (NASDAQ:IOVA).
How Does BG&G Help Investors in Securities Fraud Investigations?
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.
We handle cases on a contingency fee basis — we advance all litigation costs on your behalf. There is no fee unless we are successful.
“Our practice centers on restoring investor capital and ensuring corporate accountability, which serves to uphold the essential integrity of the marketplace.”